Showing 2351-2360 of 5644 results for "".
- Harvard Eye Associates Surgeons Implant the First AccuraSee IOPCL to Treat Macular Degenerationhttps://modernod.com/news/harvard-eye-associates-surgeons-implant-the-first-accurasee-iopcl-to-treat-macular-degeneration/2480721/Harvard Eye Associates reported that its surgeons have implanted the first AccuraSee Intraocular Pseudophakic Contact Lens (IOPCL) to improve near vision in patients with macular degeneration. The AccuraSee lens implant is placed to help magnify images and allow patients to use parts of
- New Multi-Language Options Now Available on Reichert.comhttps://modernod.com/news/new-multi-language-options-now-available-on-reichertcom/2480719/Reichert Technologies, a business unit of Ametek, has announced that Reichert.com is now available in five new language options: Chinese, French, German, Italian, and Spanish. Putting customers first will always be Reichert’s main focus. This new capability will help make the information on
- Evmann Creates Roadmap to Facilitate its Development into a €1 Billion Global Companyhttps://modernod.com/news/evmann-creates-roadmap-to-facilitate-its-development-into-a-eur1-billion-global-company/2480714/Dutch Evmann Investments Holding, the parent company of VSY Biotechnology, organized its 2022 Global Leadership Meeting last week in line with its strategic plans to become a "unicorn" company. "Unicorn" is a term used in the venture capital industry to describe 
- Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP)https://modernod.com/news/kiora-pharmaceuticals-granted-orphan-drug-designation-for-kio-301-an-investigational-drug-for-the-treatment-of-retinitis-pigmentosa-rp/2480706/Kiora Pharmaceuticals has received orphan drug designation from the FDA for its investigational treatment of retinitis pigmentosa, KIO-301. Kiora expects to initiate clinical trials of KIO-301 in Q3 2022. Orphan drug designation provides for facilitated development discussions with the FDA,
- Nominations Now Being Accepted for NORA Awardshttps://modernod.com/news/nominations-now-being-accepted-for-nora-awards/2480704/Nominations are now being accepted by the Neuro-Optometric Rehabilitation Association, International (NORA) for the following awards, which acknowledge individuals and organizations for important contributions to the area of neuro-optometric rehabilitation. The Advancement
- Apellis' Pegcetacoplan Showed Continuous Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-pegcetacoplan-showed-continuous-and-clinically-meaningful-effects-at-month-18-in-phase-3-derby-and-oaks-studies-for-geographic-atrophy-ga/2480701/Apellis Pharmaceuticals announced longer-term data from the phase 3 DERBY and OAKS studies, which showed that intravitreal pegcetacoplan, an investigational, targeted C3 therapy, continued to reduce geographic atrophy (GA) lesion growth and demonstrate a favorable safety profile at month 18 for t
- Lumibird Medical Launches New Website Dedicated to Laser Therapies for Each Glaucoma Stagehttps://modernod.com/news/lumibird-medical-launches-new-website-dedicated-to-laser-therapies-for-each-glaucoma-stage/2480684/Lumibird Medical announced the launch of its new website: www.glaucoma-laser-assisted-solutions.com, which details the treatment options at every stage of the disease paradigm: 1. SLT - A first-line treatment for g
- Fera Pharmaceuticals Obtains Orphan Drug Designation from the FDA for Naproxcinod for the Treatment of Sickle Cell Diseasehttps://modernod.com/news/nicoxs-partner-fera-pharmaceuticals-obtains-orphan-drug-designation-from-the-us-fda-for-naproxcinod-for-the-treatment-of-sickle-cell-disease/2480673/Nicox SA and Fera Pharmaceuticals announced that the FDA has granted Orphan Drug Designation for naproxcinod for the treatment of sickle cell disease, which affects an estimated 100,000 Americans. Naproxcinod is a nitr
- TearSolutions Meets with FDA and Announces Next Steps in the Development of Lacripephttps://modernod.com/news/tearsolutions-meets-with-fda-and-announces-next-steps-in-the-development-of-lacripep/2480661/TearSolutions, the developer of a replacement therapy for the treatment of dry eye disease (DED) called Lacripep, announced that in late 2021 it received official minutes from a Type C meeting with the FDA regarding the development of Lacripep for the treatment of DED and is planni
- Italian Patients Receive Samsara Vision’s SING IMT, a New Technology for Age-Related Macular Degenerationhttps://modernod.com/news/italian-patients-receive-samsara-visions-sing-imt-a-new-technology-for-age-related-macular-degeneration/2480658/Samsara Vision announced the first three successful clinical cases in Italy using its SING IMT (Smaller-Incision New-Generation Implantable Miniature Telescope) for people living with late-stage, age-related macular degeneration (AMD). The SING IMT was successfully implanted in patients